Bri ef episodes of myocardial ischemia render the myocardium resistant to subsequent longer periods of ischemia. 1 This phenomenon, known as ischemic preconditioning, consists of 2 time windows: an early phase which begins within a few minutes after an ischemic stimulus and lasts for 2 to 3 h, and a late phase which occurs 12 to 24 h after the preconditioning stimulus and lasts for 3 to 4 d. 2 Drugs including volatile anesthetics mimic myocardial ischemic preconditioning and are able to induce early preconditioning in different animal species 3, 4 as well as in humans. 5 Volatile anesthetics have been found to induce late preconditioning, 6 -8 although this effect may be species dependent. 9 In addition to volatile anesthetics, the noble gas xenon has been demonstrated to induce early myocardial preconditioning 10 via activation of several signal transduction kinases. 11, 12 However, in contrast to volatile anesthetics, whether xenon also produces late myocardial preconditioning is not known.
Cyclooxygenase (COX) is a prostaglandin synthetase that mediates the conversion of arachidonic acid to prostaglandin H2. In contrast to the constitutively expressed isoform COX-1, COX-2 is inducible in response to proinflammatory stimuli and is considered to be an important mediator of inflammation. 13 Both ischemic late preconditioning (i-LPC) and volatile anesthestic-mediated late preconditioning have been shown to involve COX-2 pathways. 14, 15 Moreover, i-LPC increases COX-1 and 2 expression and enhances myocardial concentrations of prostaglandins prostaglandin E2 and 6-keto-PGF1␣ after 24 h. 16 In the present study, we tested the hypothesis that xenon inhalation 24 h before myocardial ischemia induces late myocardial preconditioning in rat hearts in vivo. We further sought to evaluate the role of COX-2 in mediating late xenon myocardial preconditioning (Xe-LPC).
METHODS
The study was performed in accordance with the regulations of the German Animal Protection Law and was approved by the Bioethics Committee of the District of Dü sseldorf, Germany.
Animal Preparation
One hundred twelve male Wistar rats (200 -250 g) were subjected to this study. However, 10 animals died from surgical complications after coronary artery occluder implantation. Another 10 animals died of ventricular fibrillation or uncontrollable bleeding during the preparation for the ischemic or xenon preconditioning experiments.
After the depth of anesthesia was deemed adequate (by lack of muscle movement and absence of palpebra reflex), a left thoracotomy was performed in the fourth intercostal space and the pericardium opened. The left anterior descending coronary artery was identified and encircled with 2 5-0 prolene sutures (Ethicon 5/0, 1-metric, TF, Johnson and Johnson Medical BV, Norderstedt, Germany). A silicone tube (1.0 mm internal diameter, Roth, Karlsruhe, Germany) was tunneled subcutaneously and externalized between the scapulae. The internal end was placed close to the sutures around the coronary artery. The two sutures were then externalized through this tube and the tube was filled with petroleum gel to prevent pneumothorax. The chest wound was closed in layers and covered by a vest (rat jacket, size M, Byron, Grand Island, NY) to protect the tube and the externalized sutures. Postoperative analgesia was provided by intercostal blockade and wound infiltration with 0.5% bupivacaïne. The animals received antibiotic prophylaxis with cefazolin (35 mg kg Ϫ1 ). Postoperatively, the animals had free access to food and water and were under close observation by an animal care specialist in the animal care department of the University of Dü sseldorf.
Late Preconditioning Protocols
The animals were randomly assigned to five groups using sealed envelopes ( Fig. 1A ). There were eight animals per group for the myocardial infarct size measurement studies and four per group for the Western Blot analyses (discussed below). The animals were anesthetized with isoflurane 7 d after the prior procedure.
Ischemic preconditioning was induced by tightening of the previously placed suture around the coronary artery for 5 min. Myocardial ischemia was verified by the immediate occurrence of electrocardiogram (ECG) ST segment elevation. At the end of the 5-min period of coronary artery occlusion, the suture was released and removed to ensure proper reperfusion. This was verified by the disappearance of the ECG changes.
Animals in the XE-LPC groups were sedated with the i.p. injection of s-ketamine (250 mg kg Ϫ1 ). After tracheal intubation, their lungs were ventilated with 70% xenon and 30% oxygen for 15 min. The animals of the COX-2 inhibitor groups received 5 mg kg Ϫ1 NS-398 (in saline) i.p. with or without subsequent xenon preconditioning. The animals were then allowed to recover. After the ischemic and xenon preconditioning studies, the animals were transfered back in their cages and were closely observed by the investigators for at least 1 h. After this period, the animals were brought back into the animal care facility for housing under the previously described conditions.
Myocardial Infarction Size Determination
Twenty-four hours after completing the respective preconditioning protocol, the rats were anesthetized by an i.p. injection of S (ϩ)-ketamine (250 mg kg Ϫ1 ). Surgical preparation was then performed as previously described. 17 The right jugular vein was cannulated and a continuous infusion of ␣-chloralose (25 mg kg Ϫ1 ) administered. A polyethylene catheter was inserted into the descending aorta via a carotid artery and connected to a pressure transducer for measurement of aortic pressure. All animals were connected to an ECG monitor. A temperature probe was placed sub-diaphragmatically and body temperature was maintained constant at 37.9 Ϯ 0.7°C by adjusting a heating pad and a warming lamp. Arterial blood gases were analyzed at baseline, during ischemia and reperfusion and kept within physiological range.
Twenty-five minutes of myocardial ischemia was induced by tightening the coronary artery occluder and verified by the appearance of epicardial cyanosis and ECG changes. After 120 min of reperfusion, the heart was excised and myocardial infarct size was determined as previously described. 17 Briefly, hearts were mounted on a modified Langendorff apparatus for perfusion with ice cold normal saline via the aortic root at a perfusion pressure of 40 cm H 2 O in order to wash out intravascular blood. After 5 min of perfusion, the coronary artery was re-occluded and the remainder of the myocardium was perfused through the aortic root with 0.2% Evans blue in normal saline for 10 min. Intravascular Evans blue was then washed out by perfusion for 5 min with normal saline. This treatment identified the area at risk (AAR) as unstained. The heart was then cut into 2 mm transverse slices. The slices were stained with 0.75% triphenyltetrazolium chloride solution for 10 min at 37°C, fixed in 4% formalin solution for 6 h at room temperature. The myocardial AAR and the infarcted area were determined by planimetry using SigmaScan Pro 5 ® computer software (SPSS Science Software, Chicago, IL) and corrected for dry weight.
Western Blot Assay
Animals in the Western Blot portion of the study were assigned to one of three groups as shown in Fig.  1B . To exclude any confounding effect of anesthesia on Western Blot assay, the rats were decapitated. At the respective time points (n ϭ 4 for each time period), the hearts were quickly excised (Sham, 0 h, 2 h, 4 h, 8 h, 12 h, 24 h) after the respective treatment of Xe-or i-LPC. The excised hearts were washed in ice cold saline solution and frozen in liquid nitrogen. The frozen tissue was pulverized and dissolved in lysis buffer containing the following ingredients: Tris base, ethylene glycol tetraacetic acid, sodium fluoride and sodium orthovanadate, as phosphatase inhibitors (all from Sigma-Aldrich Chemicals, Taufkirchen, Germany), and a freshly added protease inhibitor mix [aprotinin, leupeptin and pepstatin] and dithioerythriol (all from Merck-Eurolab, Munich, Germany). The solution was vigorously homogenized on ice (Homogenizer, IKA) and then centrifuged at 1000g, 4°C, for 10 min. The supernatant, containing cytosolic fraction, was centrifuged again at 16,000g, 4°C, for 15 min to purify this fraction.
COX-2 expression in the myocardial tissue was determined using infrared Western Blot analysis as previously described. 18 After protein determination by the Lowry et al. method, 19 equal amounts of the homogenate were mixed with mercaptoethanol and sodium dodecyl sulfate (SDS) polyacrylamid and boiled at 95°C with loading buffer containing Trishydrochloride, glycerol and bromphenol blue. Using SDS as an anionic detergent produces proteins covered with a negative charge. These proteins than can be separated by SDS gel electrophoresis according to their size. The negatively charged proteins were transferred to an Immobilon-fluorescence membrane (Millipore, Schwalbach, Germany) using an electric current. Using the electric current enables the proteins to migrate from the gel to the membrane. COX-2 and ␣ tubuline were detected using specific antibodies binding to these two enzymes on the membrane (Monoclonal mouse anti-␣-tubulin antibody, Sigma-Aldrich, Taufkirchen, Germany; total COX-2 rabbit polyclonal antibody, Biomol, Hamburg, Germany). Nonspecific binding of the antibody was blocked by a 2 h incubation with 5% fat dry milk powder solution in Tris buffered saline containing Tween.
After washing the membrane in fresh, cold Tris buffered saline containing Tween, secondary antibodies conjugated with infrared-dye 700 or infrared-dye 800 (Biomol, Hamburg, Germany) were applied. Protein bands on the membrane were visualized and quantified by the Odyssey infrared imager ® (Licor Biosciences, Bad Homburg, Germany).
Equal loading of the protein to the SDS gel electrophoresis gel was ensured by Coomassie blue staining (Coomassie brillant blue ® , Serva Electrohoresis GmbH, Heidelberg, Germany) of each gel. 20 The results are presented as ratio of total protein to ␣-tubulin, which was used as internal standard. 
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Statistical Analysis-Sample Size Calculation
Sample size calculations were performed using GraphPad StatMate™ Version 1.01 (GraphPad Software, San Diego, CA). A sample size of eight animals in each group allowed for the detection of a difference in myocardial infarct size of 30% between control and the preconditioning groups or the preconditioning groups and the NS-398 COX-2 inhibitor group, respectively, with a power of 95% and an ␣ Ͻ 0.05. For PCR and Western Blot assay experiments, four animals in each group allows for the detection of a difference in protein expression between groups of 30% with a power of 95%, a standard deviation of 10, and an ␣ Ͻ 0.05.
Statistical analysis of the hemodynamic variables was performed by two-way repeated measures analysis of variance (ANOVA) for time and treatment (experimental group) effects. If an overall significance was found, comparisons between groups were made for each time point using one-way ANOVA followed by Dunnett's post hoc test with the control group as the reference group. Time effects within each group were analyzed by repeated-measures ANOVA followed by Dunnett's post hoc test with the baseline value as the reference time point. PCR and Western Blot data were analyzed by one-way ANOVA followed by Dunnett's post hoc test with the control group as the reference group (Graph Pad Prism version 4.00). Differences in myocardial infarct size were analyzed by ANOVA followed by Student's t-test with Bonferroni correction for multiple testing. Data are expressed as mean Ϯ sd and P Ͻ 0.05 was considered statistically significant. Table 1 shows the heart rate and mean aortic pressure during the different experimental protocols. There were no differences between the experimental groups at baseline or during during myocardial ischemia. At the end of the reperfusion period, heart rate and mean aortic pressure were lower in the groups receiving the COX-2 inhibitor NS-398 compared with baseline values. Heart rate was slower in the animals receiving NS-398 without xenon, compared with the control animals after 60 and 120 min of reperfusion.
RESULTS
Hemodynamic Results
Myocardial Infarct Size
Myocardial infarct size as a percentage of the AAR in the experimental groups is shown in Fig. 2 . Xe-LPC (31 Ϯ 8%) and i-LPC (29 Ϯ 7%) reduced myocardial infarct size, compared with the control animals (64 Ϯ 6%, P Ͻ 0.0001). Administration of the COX-2 inhibitor NS-398 blocked the reduction in myocardial infarction size observed with Xe-LPC (NS-398 ϩ Xe-LPC, 61 Ϯ 6%, P ϭ 0.0001 vs Xe-LPC), but it had no effect on myocardial infarct size when administered alone (NS-398 61 Ϯ 7%, P ϭ 1.0 vs control).
COX-2 Messenger Ribonucleic Acid and Protein Expression
Results for the COX-2 messenger ribonucleic acid (mRNA) and protein expression experiments are shown in Fig. 3 Fig. 3B ). Similar to the results of for the mRNA analysis, there was a time-dependent increase in COX-2 protein expression after i-LPC with a maximum increased level occurring 4 h after myocardial ischemia (P ϭ 0.417 vs Controls, Fig. 4A ). There was no timedependent change in COX-2 protein expression in Xe-LPC (Fig. 4B ).
DISCUSSION
The present data show that the noble gas xenon induces a late phase of myocardial preconditioning in rat hearts in vivo. The magnitude of protection is similar to that resulting from late myocardial ischemic preconditioning. Furthermore, we demonstrated that COX-2 blockade abolished the cardioprotective effect of Xe-LPC (Fig. 2) . Moreover, i-LPC increased the expression of COX-2 mRNA and protein in a timedependent manner, but there was no difference in COX-2 mRNA and protein expression observed after xenon late myocardial preconditioning.
In various animal species, xenon has been shown to have cardioprotective effects including early myocardial preconditioning in rats 10,21 and a reduction of myocardial reperfusion injury (postconditioning effect) in rabbits in vivo. 22 Possible mechanisms for xenon-induced early cardioprotection like protein kinase C, p38 mitogene activated protein kinase, heat shock protein 27, K ATP channels and phosphatidyl inositol dependent kinase 1 have been identified. 10 -21 However, there are no prior data on whether xenon exposure leads to late myocardial preconditioning and, if so, the potential mediators of this effect. It has been shown that cardioprotection by i-LPC and volatile anesthetic induced late preconditioning are mediated by complex pathways including COX-2. 14, 15 However, the literature also suggests that involvement of COX-2 might be differentially regulated in ischemic and anesthetic-induced late preconditioning.
i-LPC increases COX-1 and 2 expression and enhances myocardial concentrations of prostaglandins E2 and 6-keto-PGF1␣ in rabbits. 16 In isofluraneinduced late preconditioning in rabbits, the COX-2 inhibitor celecoxib effectively blocked the infarct sizereducing effect of the volatile anesthetic. 15 However, an effect of isoflurane on COX-1 and COX-2 protein expression was not observed. These data are in line with our findings showing that the myocardial infarct size-limiting effect of Xe-LPC can be blocked by inhibition of COX-2 activity independently of an upregulation of COX-2 mRNA and protein. These results suggest that pharmacological late preconditioning depends more on an increased activity of existing COX-2 rather than a transcriptional upregulation of COX-2 mRNA. In contrast, these results suggest that i-LPC requires upregulation of COX-2 mRNA and protein expression. Nonetheless, it must be considered that early anesthetic myocardial preconditioning 17 involves a time-dependent upregulation of intracellular enzymes that could also exist in late anesthetic preconditioning. In rabbits, the signaling pathways of i-LPC differ 24 or 72 h after the preconditioning stimulus. 23 Only 72 h after the preconditioning ischemia, myocardial levels of COX-2 mRNA, protein and cardioprotective prostaglandins were found to be increased. 23 In our experiments, we did not observe an increase in COX-2 mRNA or protein 0 to 24 h after xenon preconditioning, but we did not measure COX-2 mRNA and protein level 72 h after preconditioning.
In addition to COX-2, inducible nitric oxide synthase (iNOS) 24, 25 and mitochondrial K ATP channels 26 have been shown to be involved in i-LPC. Mitochondrial K ATP channels have been shown to be also involved in xenon-induced early preconditioning. 21 Most importantly, nitric oxide, produced by iNOS, induces preconditioning 27 via activation of COX-2 28, 29 and prostaglandins generated by COX-2 may reduce infarct size by activating the opening of K ATP channels. 30 These data indicate that the protective effects of ischemic preconditioning on the myocardium via COX-2 is a complex interaction between iNOS, nitric oxide, prostaglandins and K ATP channel opening.
However, which other pathways surrounding COX-2 might also play a role in Xe-LPC cannot be answered from our results. Moreover, COX-2 implementation in Xe-LPC must rely on indirect evidence from the pharmacological blockade of COX-2.
NS398 alone had remarkable hemodynamic effects during the reperfusion period. This is thought to be a random effect rather than a specific pharmacological side effect of NS398, a highly selective COX-2 blocker.
In this study only a single concentration of xenon was used and our results must be restricted to this concentration. Notably, xenon preconditioning may occur independent of any anesthetic effect, as other noble gases without anesthetic properties, such as helium, are also able to dispay cardioprotective effects. 31 In our study, xenon cardioprotection was only examined after 25 min of myocardial ischemia. Whether xenon cardioprotection occurs after longer periods of occlusion cannot be answered from this study.
In summary, the present results show that the noble gas xenon induces late myocardial preconditioning in rat hearts in vivo. The results further indicate differences in the involvement of COX-2 between i-LPC and Xe-LPC. Although the latter involves changes in the activity of existing COX-2, the former appears to depend on the upregulation of COX-2 mRNA and protein expression.
